 | Up a level |
Journal Article
O'Brien, Susan, Jones, Jeffrey A., Coutre, Steven, Mato, Anthony R., Hillmen, Peter, Tam, Constantine, Osterborg, Anders, Siddiqi, Tanya, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael, Call, Timothy G., Brown, Jennifer R., Stevens-Brogan, Michelle, Li, Yunfeng, Fardis, Maria, Clow, Fong, James, Danelle F., Chu, Alvina D., Hallek, Michael and Stilgenbauer, Stephan (2014). Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE (TM)-17 Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
O'Brien, Susan, Jones, Jeffrey A., Coutre, Steven E., Mato, Anthony R., Hillmen, Peter, Tam, Constantine 
ORCID: 0000-0002-9759-5017, Osterborg, Anders, Siddiqi, Tanya ORCID: 0000-0001-5292-8298, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael J., Call, Timothy G., Brown, Jennifer R., Stevens-Brogan, Michelle, Li, Yunfeng, Clow, Fong, James, Danelle F., Chu, Alvina D., Hallek, Michael and Stilgenbauer, Stephan
(2016).
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Lancet Oncol., 17 (10).
S. 1409 - 1419.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
Stilgenbauer, Stephan, Jones, Jeffrey A., Coutre, Steven, Mato, Anthony R., Hillmen, Peter, Tam, Constantine, Osterborg, Anders, Siddiqi, Tanya, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael, Call, Timothy G., Brown, Jennifer R., Li, Yunfeng, Eckert, Karl, Chang, Betty Y., James, Danelle F., Chu, Alvina D., Hallek, Michael and O'Brien, Susan (2015). Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020